Benzene and Acute Myeloid Leukemia: Clinical Evidence Review of Causation

From General Health Information to Occupational Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of environmental risks. Within this broad context, discussions of chemical exposures have historically focused on community-level concerns, emphasizing preventive measures and broad safety guidelines. This heritage provides a necessary baseline for recognizing how everyday environments may harbor substances requiring careful management. As scientific inquiry has matured, attention has increasingly turned from generalized health advisories toward more specific, occupationally relevant scenarios. In industrial settings, where exposure levels can be substantially higher and more sustained than in the general environment, the need for precise risk characterization becomes paramount. This pivot from a general health context to occupational exposure concern is particularly salient when examining substances such as benzene. The transition requires acknowledging that while public health information offers valuable foundational knowledge, the concentrated and repeated exposures found in workplaces demand a distinct analytical framework. Shifting focus from broad population health to the conditions faced by workers allows for a more targeted evaluation of potential hazards. This occupational lens reframes the discussion, moving from general awareness to the specific circumstances of those whose daily activities may involve contact with industrial chemicals.

Benzene as a Myelotoxin and Carcinogen: Mechanistic Pathways

Benzene is a recognized myelotoxin and carcinogen, with chronic exposure linked to an increased risk of acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/34069279/). Occupational exposure to benzene at levels of 10 ppm or more has been associated with elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). The mode of action for benzene-induced AML is understood to involve multiple key events, including hematotoxicity and genetic toxicity observable in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). These early events precede the development of myelodysplastic syndromes (MDS) and AML, and preventing them would reduce morbidity and mortality from these outcomes (https://pubmed.ncbi.nlm.nih.gov/33429013/). Mechanistic pathways linking benzene to AML include genotoxic effects, oxidative stress and inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, genetic alterations alone are insufficient to fully explain the onset of hematologic malignancies, suggesting that epigenetic changes also play a role (https://pubmed.ncbi.nlm.nih.gov/34069279/). Benzene exposure has been associated with altered gene expression in hematologic neoplasms, indicating that epigenetic mechanisms contribute to its carcinogenicity (https://pubmed.ncbi.nlm.nih.gov/34069279/).

Epidemiologic Evidence and Risk Assessment

Epidemiologic evidence supports a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). A study using the Swiss National Cohort linked occupational benzene exposure, assessed via a quantitative job-exposure matrix, to increased mortality from lymphohaematopoietic cancers, including AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). Additionally, a meta-analysis of 25 studies found that benzene exposure was associated with an increased risk of childhood AML, with an odds ratio of 1.22 per 1 μg/m³ increase in benzene exposure (95% CI: 1.02-1.46) (https://pubmed.ncbi.nlm.nih.gov/41485753/). This analysis also reported elevated risks for all childhood cancers combined (OR: 1.12, 95% CI: 1.02-1.22) (https://pubmed.ncbi.nlm.nih.gov/41485753/). Risk assessment for benzene-induced AML can be improved by integrating data from multiple sources. A Bayesian meta-regression model that combined six human AML studies, three human leukemia studies, ten human biomarker studies, and four experimental animal studies estimated the exposure-response curve for benzene and AML (https://pubmed.ncbi.nlm.nih.gov/34906966/). A linear meta-regression model with intercept best predicted AML risks after cross-validation, both for the full dataset and for AML studies alone (https://pubmed.ncbi.nlm.nih.gov/34906966/). This approach highlights the value of incorporating human biomarker and animal data to inform risk models when human AML data are sparse across the exposure range (https://pubmed.ncbi.nlm.nih.gov/34906966/).

Causation Considerations and Implications for Warnings

For affected patients, causation considerations include the timeline between benzene exposure and documented harm. The mode of action for AML development involves multiple key events that occur over time, with hematotoxicity and genetic toxicity serving as early indicators (https://pubmed.ncbi.nlm.nih.gov/33429013/). Occupational exposure at levels of 10 ppm or more has been linked to increased AML risk, but lower-level exposures may also contribute, as suggested by the meta-analysis showing elevated childhood AML risk at ambient levels (https://pubmed.ncbi.nlm.nih.gov/41485753/). The latency period between benzene exposure and AML diagnosis can vary, but the sequential nature of key events—from hematotoxicity to MDS to AML—provides a framework for understanding the timeline (https://pubmed.ncbi.nlm.nih.gov/33429013/). Adequacy of warnings regarding benzene and AML is informed by the strength of the evidence. Previous studies have established a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). However, mixed results have been reported for associations with other myeloid and lymphoid malignancies, indicating that warnings should specifically address AML risk (https://pubmed.ncbi.nlm.nih.gov/38727681/). The recognition of benzene as a myelotoxin and its ability to increase risk for AML, MDS, aplastic anemia, and lymphomas underscores the need for comprehensive warnings that cover these outcomes (https://pubmed.ncbi.nlm.nih.gov/34069279/). The incorporation of key event information into risk models could further refine exposure limits and improve preventive measures (https://pubmed.ncbi.nlm.nih.gov/33429013/). In summary, the clinical evidence supports a causal link between benzene exposure and AML, with mechanistic pathways involving genotoxicity, oxidative stress, inflammation, immunosuppression, and epigenetic alterations. Occupational exposure at levels of 10 ppm or more is associated with increased AML risk, and ambient exposure has been linked to childhood AML. Risk assessment models that integrate human, biomarker, and animal data provide a robust basis for understanding the exposure-response relationship. Warnings should reflect the established causal relationship and the range of hematologic malignancies associated with benzene.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence linking benzene to acute myeloid leukemia?

Benzene is a recognized myelotoxin and carcinogen, with chronic exposure linked to an increased risk of acute myeloid leukemia (AML) (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epidemiologic evidence supports a causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/). Mechanistic pathways include genotoxicity, oxidative stress, inflammation, immunosuppression, and epigenetic alterations.

What levels of benzene exposure are associated with increased AML risk?

Occupational exposure to benzene at levels of 10 ppm or more has been associated with elevated AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). Additionally, a meta-analysis found that ambient benzene exposure was linked to childhood AML, with an odds ratio of 1.22 per 1 μg/m³ increase (https://pubmed.ncbi.nlm.nih.gov/41485753/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.